Siemens Healthineers : Q2 a straight beat on rapid antigen test sales
>€ 680m in rapid antigen test sales in Q2 vs € 380m estimated - The company had a strong Q2 2021-22 with comparable sales growth of 15.8% y-o-y vs our forecast and consensus of 9.0% to 9.4% y-o-y. The adj. EBIT margin came in at 17.9% vs 17.8% our forecast and 17.5% consensus. The beat was c. 4% on sales and between c. 4% and 7% on adj. EBIT. Adj. EPS of € 0.67 was even 14% and 18% ahead of our forecast and consensus, respectively. The beat was solely driven by rapid ...Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services trough expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value. Siemens AG is a majority shareholder of the Company. The Company is active worldwide.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.